What is SCYNEXIS, Inc. (SCYX)?

SCYNEXIS, Inc. (SCYX) is a stock in the Healthcare sector, Medical - Pharmaceuticals industry. View full analysis on Stocks360.

What is the current price of SCYX?

The current price of SCYX is $3.86. Prices are updated in real time on Stocks360.

What is SCYX's price-to-earnings (PE) ratio?

SCYX's trailing twelve-month PE ratio is -2.10, based on current price and earnings per share data available on Stocks360.

What is SCYX's market capitalization?

SCYX's market capitalization is $24,274,448.00, placing it in the small-cap tier.

SCYNEXIS, Inc. (SCYX)

Stock analysis · NASDAQ · Healthcare · Medical - Pharmaceuticals

$3.86

Market Cap

$24.27M

PE (TTM)

-2.10

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

1.06

Day Range

$3.72 – $4.01

52-wk Range

$3.53 – $9.12

Avg Volume

N/A

Volume

133.50K

SCYNEXIS, Inc. (SCYX) is a publicly traded company in the Healthcare sector. Latest price: $3.86. Market cap $24.27M. Trailing PE -2.10. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

You have viewed 8 SEO analysis pages

Unlock saved watchlists, personalized setups, and referral credits with a free Stocks360 account.

Continue with free signup

1-Year Price

2025-10-30 · $5.50 2026-10-29 · $3.86 (-29.82%)

Earnings

Most Recent

Aug 10, 2026

EPS $0.63 vs est. $-0.51

Beat by $1.14

Next Earnings

Nov 4, 2026

EPS estimate $-0.72

Proprietary Signals

Signal snapshot temporarily unavailable.

About SCYNEXIS, Inc.

SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-2.10×
P/S (TTM)	1.26×
P/B	0.68×
PEG	0.01×
P/FCF (TTM)	-1.82×
EV / EBITDA	-1.54×
EV / Sales	0.82×
Earnings Yield	-22.43%
Free Cash Flow Yield	-54.83%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$15.73M
Revenue (TTM)	$19.21M
Net Income (TTM)	-$5.44M
Free Cash Flow (TTM)	-$13.31M
Net Debt	-$8.54M
Working Capital	$50.41M
Gross Margin	100.00%
Operating Margin	-117.61%
Net Margin	-53.27%
Return on Equity	-21.10%
Return on Invested Capital	-32.44%